Evidence map›Paper›PMID 39021173›Full record

ReviewCurrent medicinal chemistry2025

Revolutionizing Antibacterial Strategies: Lipid Nanoparticles as Game-changers in Combatting Multi-drug-resistant Infections.

Rihana Begum P, Bhupendra G Prajapati, R Rajeshkumar, V Balasubramaniam, Sivasankaran Ponnusankar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rihana Begum PDepartment of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty 643 001, The Nilgiris, Tamil Nadu, India.
Bhupendra G PrajapatiDepartment of Pharmaceutics, Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva, 384012, India.ORCID 0000-0001-8242-4541
R RajeshkumarDepartment of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education Research, Ooty 643 001, The Nilgiris, Tamil Nadu, India.
V BalasubramaniamDepartment of Emergency Medicine, Govt. Medical College & Hospital, Ooty 643 001, The Nilgiris, Tamil Nadu, India.
Sivasankaran PonnusankarDepartment of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty 643 001, The Nilgiris, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To overcome the limits of traditional antibiotic medications, novel approaches are needed to combat the growing global epidemic of Multidrug-resistant (MDR) infections. As drug-resistant bacteria develop, the importance of innovative antimicrobial methods is underscored by antibiotic abuse and misuse. The global threat of MDR microorganisms is increasing, which calls for a coordinated global response. Lipid Nanoparticles (LNPs) possess several characteristics that make them attractive choices for managing multidrug resistant (MDR) infections, as well as potential delivery systems for antimicrobial agents. Thus, LNPs improve drug solubility, stability, and targeted delivery, thereby mitigating the drawbacks of conventional antibiotic therapy. Several characteristics of LNPs, which stop MDR bacteria from developing resistance mechanisms, serve as guidelines for precision medicine. It presents a powerful approach for combating the growing concern of MDR bacteria by increasing Anti-Microbial Peptides (AMPs) bioavailability and targeting distribution to bacterial cells. LNPs have the potential to redefine antibacterial treatments for MDR illnesses in the context of this study. Further, it discusses LNP use in larger applications, such as fighting Anti-Microbial Resistance (AMR) and MDR. A complete understanding of the unique features, many uses, and importance of collaborative efforts to overcome the global challenge of antibiotic resistance are also conveyed in the study.

Indexed as

Anti-Bacterial AgentsBacteriaBacterial InfectionsDrug Resistance, Multiple, BacterialLipidsNanoparticlesAnimalsHumansLiposomesAnti-Bacterial AgentsLipid NanoparticlesLipidsLiposomesAntimicrobial resistancehealth care crisisinnovation therapieslipid nanoparticlesmulti-drug resistant infectionsnovel approaches

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.